orphan drug
Entity, reached from Hormuz.
- Evidence
- 47 documents · 17 separate publishers
- Standing
- Added automatically from coverage
- Time
- first seen 8 Jul 2026, last seen 9 Oct 2026
- Measured
- 53% of mentions say something specific about it; the rest only name it
- As of
- 10 Oct 2026
Where this comes from
- The Clinical Trial Vanguard · 2026-09-24 · FDA Approves Lyrfigtu for FGFR2-Rearranged Cholangiocarcinoma (opens the source in a new tab)
- FDA · 2026-09-08 · Rare Diseases at FDA (opens the source in a new tab)
- FDA Drug News · 2026-07-08 · Medical Products for Rare Diseases and Conditions (opens the source in a new tab)
What is claimed about it
Situations it is named in
Who it moves with
- co-mentioned with fda (44 documents)seen together
- co-mentioned with drug administration (21 documents)seen together
- co-mentioned with priority review (18 documents)seen together
- co-mentioned with breakthrough therapy (15 documents)seen together
- co-mentioned with clinical trial (13 documents)seen together
- co-mentioned with fda-approved (11 documents)seen together
- co-mentioned with u.s. food (11 documents)seen together
- co-mentioned with clinical trials (10 documents)seen together
- co-mentioned with adverse events (9 documents)seen together
- co-mentioned with nasdaq (8 documents)seen together